Treating the Underlying Causes of Age-Related Disease

Cyclarity develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.

The company's technology removes arterial plaque by clearing the non-degradable cholesterol that accumulates within cells in the arterial walls.

Cyclarity's long-term goal is to deliver a simple and affordable preventive therapy for the world.

Our products are based on novel derivatives of a well-known, safe compound, and a new way of looking at cardiovascular disease.

Curing age-related disease

  • through damage repair 
  • using simple, direct, rationally designed drugs

... starting with

  • the first true disease-modifying treatment for atherosclerosis

... based on

  • a novel class of well-known, safe compounds called cyclodextrins

... driven by

  • a new perspective on cardiovascular disease
  • with a launch of $4M 
  • to carry development through candidate selection and lead testing
  • Raise of additional $10M 
  • to carry development through to initial filings with regulatory agency for human clinical trials
  • Underdog Pharmaceuticals rebrands to Cyclarity Therapeutics

Cyclarity is continuing to develop technology to treat, cure, and reverse atherosclerosis.

Cyclarity Pharmaceuticals, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.